Clinical trial
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
NCT02957968 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
- Lead sponsor
- Virginia Commonwealth University
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 24, 2017
- Completion date
- March 31, 2027
- Enrollment
- 46 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
breast adenocarcinoma, estrogen receptor- negative breast cancer, estrogen receptor-positive breast cancer, her2/neu negative, invasive breast carcinoma, progesterone receptor negative, progesterone receptor positive tumor, stage ii breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, triple-negative breast carcinoma